Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Chronic gout Clinical criteria: The condition must be either chronic gouty arthritis or chronic tophaceous gout, AND Patient must have a medical contraindication to allopurinol; OR Patient must have a documented history of allopurinol hypersensitivity syndrome; OR Patient must have an intolerance to allopurinol necessitating permanent treatment discontinuation.
“Febuxostat is a non-purine selective inhibitor of XO which inhibits human xanthine oxidase under in vitro conditions with a dissociation constant (Ki) of 10 nM.”
“Febuxostat has an apparent mean terminal elimination half-life (t1/2) of approximately 5 to 8 hours.”
“In vitro studies with human liver microsomes showed that those oxidative metabolites were formed primarily by CYP1A1, CYP1A2, CYP2C8 or CYP2C9 and febuxostat glucuronide was formed mainly by UGT 1A1, 1A8, and 1A9.”
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.